Roche(US:RHHBY) Jing Ji Guan Cha Wang·2026-02-12 20:28Company Overview - Shodex Bio (GPCR.OQ) has entered into a non-exclusive patent licensing agreement with Roche and Genentech, receiving a $100 million upfront payment and future royalties from oral GLP-1 drug sales [1] - The company's Q3 2025 financial report shows zero revenue and a net loss of $65.8 million, indicating ongoing R&D investments are pressuring short-term profitability [4] Stock Performance - As of February 12, 2026, Shodex Bio's stock price fell by 3.24% to $73.52, with a cumulative decline of 12.82% over the last 20 trading days [2] - The stock price peaked at $94.90 in January 2026 due to acquisition rumors but has since experienced a pullback, with a recent volatility of 22.57% and a low of $72.10 [5] Industry Context - Since January 2026, the pharmaceutical and biotechnology sector has seen accelerated thematic rotation, with profit-taking pressures emerging in the innovative drug field [3] - Concerns about intensified competition in the GLP-1 market, particularly regarding potential impacts from generic drugs, have led to increased caution among investors [3] Market Environment - On the same day, the Nasdaq index fell by 1.84%, reflecting a general increase in market risk aversion [6] - Shodex Bio's trading volume was approximately $24.58 million, indicating that low liquidity conditions may amplify stock price volatility [6]